Repare Therapeutics
Clinical trials sponsored by Repare Therapeutics, explained in plain language.
-
New cancer drug combo tested in early trial, but study halted
Disease control TerminatedThis early-phase trial tested a new drug called RP-3467, alone or combined with olaparib, in 26 adults with advanced solid tumors that had stopped responding to other treatments. The main goal was to check safety and find the right dose. The study was terminated early, so results…
Phase: PHASE1 • Sponsor: Repare Therapeutics • Aim: Disease control
Last updated May 17, 2026 03:29 UTC
-
Experimental cancer pill RP-1664 fails to launch: phase 1 trial halted
Disease control TerminatedThis early-stage study tested an experimental oral drug called RP-1664 in people with advanced solid tumors that had stopped responding to standard treatments. The goal was to find a safe dose and see if the drug could shrink tumors. The study was terminated early, and results ar…
Phase: PHASE1 • Sponsor: Repare Therapeutics • Aim: Disease control
Last updated May 14, 2026 12:06 UTC